31 Overall, although progression to macroalbuminuria just failed to reach significance in EXSCEL, less participants with baseline normoalbuminuria treated with exenatide progressed to develop albuminuria versus placebo treatment during the first 6 months of the trial (3% vs. 4%, p = 0.03), but this was mainly accounted for by less transition to microalbuminuria. 29 In the ELIXA
2
—
—
The sentences
8 A composite kidney outcome comprising macroalbuminuria, ≥40% reduction in eGFR, kidney replacement therapy, or death was reduced with exenatide therapy (5.8% exenatide versus 6.5% placebo, respectively), but this reduction just failed to reach statistical significance (HR: 0.88, 95% CI: 0.76–1.01). 28 Despite this, a kidney function composite end point of ≥30% eGFR decline or ESKD has been reported to be significantly decreased with exenatide treatment compared with placebo (HR: 0.87, 95% CI: 0.77–0.99, p = 0.03) in the EXSCEL trial. 29 Of note, and as s